Klaus Breiner

Co-founder and Managing Director

2021 - Current

We are an independent Swiss VC Firm. Our Pureos Bioventures funds focus on private biotech companies in Switzerland and broader Europe developing innovative drugs for severe diseases.

Non-executive Director

2021

Managing Partner

2017

BB Pureos Bioventures is a new venture capital franchise to exclusively invest in private innovative drug development companies with a special emphasis on the next generation of biological drugs and drug formats. For Pureos, we have assembled a new team of venture managers, biotech founders, scientists and big pharma & biotech executives, with long-standing experience in biologic drug development, company building and healthcare investing, and a wide-spanning network. We started Pureos as a joint venture with the Bellevue Group, which has a long tradition of healthcare investing, and is one of the largest and most experienced healthcare investors worldwide.

Partner

2004

Selected Investments: Alpex Pharma SA (secondary sale), AM-Pharma BV, Cadence Pharmaceuticals, Inc. (later publicly listed, subsequently acquired by Mallinckrodt), Neose Technologies, Inc. (asset acquisition), Orthocon Inc.(later merged to become AbyRx Inc.), Vaximm AG

Co-Founder & Vice-Chairman (Executive Chairman till mid-2016)

2008 - 2022

Board Director

2006 - 2021

Senior Adviser Private Equity

2004 - 2021

Board Director

2007 - 2020

Board Director

2011 - 2019

Board Director

2007 - 2011